- Full text PDF available (0)
- This year (1)
- Last 5 years (2)
- Last 10 years (4)
The chemokines CCL3 and CCL5, as well as their shared receptor CCR1, are believed to play a role in the pathogenesis of several inflammatory diseases including rheumatoid arthritis, multiple sclerosis, and transplant rejection. In this study we describe the pharmacological properties of a novel small molecular weight CCR1 antagonist, CP-481,715… (More)
The synthesis, biological activity, and pharmacokinetic profile of CCR1 antagonists are described.
To understand the reasons for global CH4 changes since the 1990s, Kai et al. evaluated a combined record of observed tropospheric CH4 mole fractions as well as dC-CH4 and dD-CH4 measurements from mid latitudes of both hemispheres. Their data set shows a strongly decreasing inter-hemispheric difference (IHD) in dC-CH4 from 20.246 0.11% during 1989–1993 to… (More)
The synthesis, biological activity, and pharmacokinetic profile of novel CCR1 antagonists are described.
Advances in the field of drug discovery have brought an explosion in the quantity of data available to medicinal chemists and other project team members. New strategies and systems are needed to help these scientists to efficiently gather, organize, analyze, annotate, and share data about potential new drug molecules of interest to their project teams.… (More)
The present manuscript details structure-activity relationship studies of lead structure 1, which led to the discovery of CCR1 antagonists >100-fold more potent than 1.
Here we describe the development of novel methods for compound evaluation and prioritization based on the structure-activity relationship matrix (SARM) framework. The SARM data structure allows automatic and exhaustive extraction of SAR patterns from data sets and their organization into a chemically intuitive scaffold/functional-group format. While SARMs… (More)